Hormonal
Tirzepatide therapy significantly improves functional capacity (6MWT distance) and quality of life (KCCQ scores) in patients with heart failure.
If you have heart failure and are prescribed tirzepatide, you may experience an increased ability to walk and an overall improvement in your quality of life within six months. This means you might feel less short of breath and more capable of performing daily activities. Discuss these potential benefits with your healthcare provider.
Functional capacity, assessed through the six-minute walk test (6MWT), demonstrated significant improvement. The mean walking distance increased from 290 ± 60 meters at baseline to 360 ± 65 meters at six months. Additionally, quality of life scores measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ) improved from a baseline mean score of 48.5 ± 10.2 to 63.4 ± 9.8 at follow-up.
Why this rating
Observational study with no control group; however, the improvements exceed minimal clinically important differences (MCID).
Source
Evaluating the Impact of Tirzepatide on Clinical Outcomes in Patients With Heart Failure
Mohammad Hamza Bin Abdul Malik et al. · Cureus · 2025
DOI 10.7759/cureus.82118
More from this paper
- Tirzepatide therapy significantly improves cardiac function (LVEF) and reduces cardiac stress (NT-proBNP) in patients with heart failure over a six-month period.Moderate
- Tirzepatide therapy significantly improves metabolic control (HbA1c, fasting glucose) and lipid profiles (LDL, HDL, triglycerides) in patients with heart failure.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →